Zentalis
Zentalis :
Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Multiple mono and combo trials are ongoing/planned across the pipeline.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
1359 Broadway
Suite 1710
New York, NY 12065
United States
Suite 1710
New York, NY 12065
United States
More info:
My account:
Company Participants at Zentalis R&D Day
- Anthony Sun, CEO
Lead Programs
ZN-c3: WEE1i
Potentially first- and best-in class oral inhibitor
| Indication | Phase |
|---|---|
| Monotherapy & Combination studies (Multiple) | 1/2 |
ZN-d5: BCL-2
Oral selective inhibitor of B-cell lymphoma 2 (BCL-2)
| Indication | Phase |
|---|---|
| Hematologic Malignancies and related disorders | 1/2 |
BCL-xL Degrader
Solid Tumors and Hematologic Malignancies
| Indication | Phase |
|---|---|
| Solid Tumors and Heme Malignancies | Pre-clinical |
Top 10 Holders of Zentalis Pharmaceuticals, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Matrix Capital Management Co. LP | 16.12 | 9,199,973 | 173.24 | 13F | 12/31/22 |
| Fidelity Management & Research Co. LLC | 11.58 | 6,607,768 | 124.42 | 13F | 12/31/22 |
| Avidity Partners Management LP | 9.02 | 5,150,000 | 96.97 | 13F | 12/31/22 |
| The Vanguard Group, Inc. | 7.22 | 4,119,537 | 77.57 | Funds | 2/28/23 |
| Vanguard Group, Inc. (Subfiler) | 7.08 | 4,039,096 | 76.06 | 13F | 12/31/22 |
| Wellington Management Co. LLP | 6.34 | 3,618,493 | 68.14 | 13F | 12/31/22 |
| State Street Corp. | 5.40 | 3,084,137 | 58.07 | 13F | 12/31/22 |
| Capital Research & Management Co. (International Investors) | 5.34 | 3,048,182 | 57.40 | 13F | 12/31/22 |
| Tybourne Capital Management (HK) Ltd. | 3.91 | 2,231,427 | 42.02 | 13F | 12/31/22 |
| T. Rowe Price Investment Management, Inc. | 3.87 | 2,210,442 | 41.62 | 13F | 12/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.